BioMarin Announces Out-licensing Plan for ROCTAVIAN

BioMarin has decided to pursue allowing another company to market and sell ROCTAVIAN, its one-time gene therapy used to treat adults with severe hemophilia A.

Source: National Bleeding Disorders Foundation, NBDF Notes, November 2025